These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 22702508)

  • 1. Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial.
    Nair P; Gaga M; Zervas E; Alagha K; Hargreave FE; O'Byrne PM; Stryszak P; Gann L; Sadeh J; Chanez P;
    Clin Exp Allergy; 2012 Jul; 42(7):1097-103. PubMed ID: 22702508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of a CXCR1/CXCR2 antagonist on neutrophil migration in mild atopic asthmatic subjects.
    Todd CM; Salter BM; Murphy DM; Watson RM; Howie KJ; Milot J; Sadeh J; Boulet LP; O'Byrne PM; Gauvreau GM
    Pulm Pharmacol Ther; 2016 Dec; 41():34-39. PubMed ID: 27640067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects.
    Holz O; Khalilieh S; Ludwig-Sengpiel A; Watz H; Stryszak P; Soni P; Tsai M; Sadeh J; Magnussen H
    Eur Respir J; 2010 Mar; 35(3):564-70. PubMed ID: 19643947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CXCR2 Antagonist MK-7123. A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease.
    Rennard SI; Dale DC; Donohue JF; Kanniess F; Magnussen H; Sutherland ER; Watz H; Lu S; Stryszak P; Rosenberg E; Staudinger H
    Am J Respir Crit Care Med; 2015 May; 191(9):1001-11. PubMed ID: 25695403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans.
    Lazaar AL; Sweeney LE; MacDonald AJ; Alexis NE; Chen C; Tal-Singer R
    Br J Clin Pharmacol; 2011 Aug; 72(2):282-93. PubMed ID: 21426372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis.
    De Soyza A; Pavord I; Elborn JS; Smith D; Wray H; Puu M; Larsson B; Stockley R
    Eur Respir J; 2015 Oct; 46(4):1021-32. PubMed ID: 26341987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD.
    Kirsten AM; Förster K; Radeczky E; Linnhoff A; Balint B; Watz H; Wray H; Salkeld L; Cullberg M; Larsson B
    Pulm Pharmacol Ther; 2015 Apr; 31():36-41. PubMed ID: 25681277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined anti CXC receptors 1 and 2 therapy is a promising anti-inflammatory treatment for respiratory diseases by reducing neutrophil migration and activation.
    Planagumà A; Domènech T; Pont M; Calama E; García-González V; López R; Aulí M; López M; Fonquerna S; Ramos I; de Alba J; Nueda A; Prats N; Segarra V; Miralpeix M; Lehner MD
    Pulm Pharmacol Ther; 2015 Oct; 34():37-45. PubMed ID: 26271598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of the CXCR2 antagonist, MK-7123, on bone marrow functions in healthy subjects.
    Hastrup N; Khalilieh S; Dale DC; Hanson LG; Magnusson P; Tzontcheva A; Tseng J; Huyck S; Rosenberg E; Krogsgaard K
    Cytokine; 2015 Apr; 72(2):197-203. PubMed ID: 25661195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of LPS-induced airway neutrophilic inflammation in healthy volunteers with an oral CXCR2 antagonist.
    Leaker BR; Barnes PJ; O'Connor B
    Respir Res; 2013 Dec; 14(1):137. PubMed ID: 24341382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of control of asthma following inhaled corticosteroid withdrawal is associated with increased sputum interleukin-8 and neutrophils.
    Maneechotesuwan K; Essilfie-Quaye S; Kharitonov SA; Adcock IM; Barnes PJ
    Chest; 2007 Jul; 132(1):98-105. PubMed ID: 17550933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Airway inflammation and cellular stress in noneosinophilic atopic asthma.
    Tsoumakidou M; Papadopouli E; Tzanakis N; Siafakas NM
    Chest; 2006 May; 129(5):1194-202. PubMed ID: 16685009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Humoral immunity and delayed-type hypersensitivity in healthy subjects treated for 30 days with MK-7123, a selective CXCR2 antagonist.
    Seiberling M; Kamtchoua T; Stryszak P; Ma X; Langdon RB; Khalilieh S
    Int Immunopharmacol; 2013 Oct; 17(2):178-83. PubMed ID: 23791619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of a selective CXCR2 antagonist (AZD5069) on human blood neutrophil count and innate immune functions.
    Jurcevic S; Humfrey C; Uddin M; Warrington S; Larsson B; Keen C
    Br J Clin Pharmacol; 2015 Dec; 80(6):1324-36. PubMed ID: 26182832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Administration of a CXC Chemokine Receptor 2 (CXCR2) Antagonist, SCH527123, Together with Oseltamivir Suppresses NETosis and Protects Mice from Lethal Influenza and Piglets from Swine-Influenza Infection.
    Ashar HK; Pulavendran S; Rudd JM; Maram P; Achanta M; Chow VTK; Malayer JR; Snider TA; Teluguakula N
    Am J Pathol; 2021 Apr; 191(4):669-685. PubMed ID: 33453177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist.
    Gonsiorek W; Fan X; Hesk D; Fossetta J; Qiu H; Jakway J; Billah M; Dwyer M; Chao J; Deno G; Taveras A; Lundell DJ; Hipkin RW
    J Pharmacol Exp Ther; 2007 Aug; 322(2):477-85. PubMed ID: 17496166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mepolizumab and exacerbations of refractory eosinophilic asthma.
    Haldar P; Brightling CE; Hargadon B; Gupta S; Monteiro W; Sousa A; Marshall RP; Bradding P; Green RH; Wardlaw AJ; Pavord ID
    N Engl J Med; 2009 Mar; 360(10):973-84. PubMed ID: 19264686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clarithromycin targets neutrophilic airway inflammation in refractory asthma.
    Simpson JL; Powell H; Boyle MJ; Scott RJ; Gibson PG
    Am J Respir Crit Care Med; 2008 Jan; 177(2):148-55. PubMed ID: 17947611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial.
    Brightling CE; Chanez P; Leigh R; O'Byrne PM; Korn S; She D; May RD; Streicher K; Ranade K; Piper E
    Lancet Respir Med; 2015 Sep; 3(9):692-701. PubMed ID: 26231288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Downmodulation of CXCL8/IL-8 receptors on neutrophils after recruitment in the airways.
    Pignatti P; Moscato G; Casarini S; Delmastro M; Poppa M; Brunetti G; Pisati P; Balbi B
    J Allergy Clin Immunol; 2005 Jan; 115(1):88-94. PubMed ID: 15637552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.